References
- Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006; 147(suppl 2): S80–S87.
- Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005; 21(1): 71–80.
- Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60(8): 959–966.
- Staskin D, Dmochowski R, Serels S, Andoh M, Hussain I, Smith N. Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin. Int Urogynecol J. 2007; 18(suppl 1): S73.
- Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005; 48(3): 464–170.
- Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother. 2006; 4(1): 14–24.
- Staskin DR, MacDiarmid SA. Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med. Mar 2006: 119(3 suppl 1): 24–28.
- Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47(3): 376–384.
- Chapple CR. Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine- controlled phase 2 dose-finding study. BJU Int. 2004; 93(1): 71–77.
- VESIcare [package insert], Deerfield, IL: Astellas Pharma, US, Inc.; 2005.
- Smulders RA, Kuipers ME, Krauwinkel WJ. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Br J Clin Pharmacol. 2006; 62(2): 210–217.
- Taekema-Roelvink ME, Swart PJ, Kuipers ME, Krauwinkel WJ, Visser N, Smulders RA. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin Ther. 2005; 27(9): 1403–1410.
- Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther. 2005; 43(5): 227–238.
- Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004; 3(1): 46–53.
- Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci. 2006; 102(4): 405–412.
- Astellas Pharma US, Inc. Astellas Worldwide Market Authorization Status. June 2007.
- Astellas Pharma US, Inc. Astellas internal data, IMS MIDAS Global Sales Audit. IMS NPA, SDI (Surveillance Data Inc.) patient longitudinal data, from August 2004 to March 2007.
- Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. Winter 2002; 9(4): 1991–1998.